Apimeds Pharmaceuticals US, Inc. (APUS)
4.55
-0.07
(-1.52%)
USD |
NYAM |
Oct 14, 11:42
Apimeds Pharmaceuticals US Net Income (Quarterly) : -20.17M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -20.17M |
| March 31, 2026 | -35.06M |
| December 31, 2025 | -1.155M |
| September 30, 2025 | -1.781M |
| June 30, 2025 | -2.662M |
| March 31, 2025 | -0.4024M |
| December 31, 2024 | -0.3116M |
| Date | Value |
|---|---|
| September 30, 2024 | -0.3325M |
| June 30, 2024 | -0.4494M |
| March 31, 2024 | -0.2965M |
| December 31, 2023 | -0.567M |
| September 30, 2023 | -0.11M |
| June 30, 2023 | -0.0361M |
| March 31, 2023 | -0.0646M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 20.17M |
| EPS Diluted (Quarterly) | -11.77 |
| Enterprise Value | 13.26M |
| Earnings Yield | -806.8% |
| Normalized Earnings Yield | -414.45 |